- Q4 2023 Fate Therapeutics Inc Earnings Call TranscriptFeb 26, 2024$6.95 (-0.14%)Earnings
- Q3 2023 Fate Therapeutics Inc Earnings Call TranscriptNov 08, 2023$2.33 (+0.87%)Earnings
- Q2 2023 Fate Therapeutics Inc Earnings Call TranscriptAug 08, 2023$3.53 (-0.56%)Earnings
- Fate Therapeutics Inc at Goldman Sachs Healthcare Conference TranscriptJun 13, 2023
- Fate Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Q1 2023 Fate Therapeutics Inc Earnings Call TranscriptMay 03, 2023$6.32 (+6.76%)Earnings
- Fate Therapeutics Inc at Barclays Global Healthcare Conference TranscriptMar 14, 2023
- Q4 2022 Fate Therapeutics Inc Earnings Call TranscriptFeb 28, 2023$6.12 (+1.83%)Earnings
- Fate Therapeutics Inc at Cowen IO Next Summit (Virtual) TranscriptNov 11, 2022
- Q3 2022 Fate Therapeutics Inc Earnings Call TranscriptNov 03, 2022$19.45 (-2.94%)Earnings
- Fate Therapeutics Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2022
- Q2 2022 Fate Therapeutics Inc Earnings Call TranscriptAug 03, 2022$32.81 (+7.12%)Earnings
- Fate Therapeutics Inc at Bank of America Healthcare Conference TranscriptMay 12, 2022
- Q1 2022 Fate Therapeutics Inc Earnings Call TranscriptMay 04, 2022$30.69 (+6.64%)Earnings
- Fate Therapeutics Inc at Barclays Global Healthcare Conference TranscriptMar 16, 2022
- Q4 2021 Fate Therapeutics Inc Earnings Call TranscriptFeb 28, 2022$34.55 (-1.09%)Earnings
- Fate Therapeutics Inc at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) TranscriptFeb 09, 2022
- Fate Therapeutics Inc Phase 1 FT516 and FT596 Clinical Data Update Call TranscriptDec 14, 2021
- Fate Therapeutics Inc Investor Event - Corporate Call TranscriptNov 15, 2021
- Q3 2021 Fate Therapeutics Inc Earnings Call TranscriptNov 04, 2021$59.65 (-1.21%)Earnings
- Fate Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 10, 2021
- Fate Therapeutics Inc Interim Phase 1 Clinical Data for NHL Programs Call TranscriptAug 19, 2021
- Q2 2021 Fate Therapeutics Inc Earnings Call TranscriptAug 04, 2021$85.73 (+2.98%)Earnings
- Fate Therapeutics Inc at Bank of America NAPA Healthcare Conference TranscriptJun 15, 2021
- Fate Therapeutics Inc Annual Shareholders Meeting TranscriptJun 02, 2021
- Fate Therapeutics Inc at Jefferies Healthcare Conference (Virtual) TranscriptJun 01, 2021
- Fate Therapeutics Inc Interim Phase 1 Clinical Data for AML Programs Corporate Call TranscriptMay 13, 2021
- Q1 2021 Fate Therapeutics Inc Earnings Call TranscriptMay 05, 2021$77.73 (-2.51%)Earnings
- Fate Therapeutics Inc at Barclays Global Healthcare Conference (Virtual) TranscriptMar 11, 2021
- Fate Therapeutics Inc at SVB Leerink Global Healthcare Conference (Virtual) TranscriptFeb 25, 2021
- Q4 2020 Fate Therapeutics Inc Earnings Call TranscriptFeb 24, 2021$95.27 (-0.22%)Earnings
- Q3 2020 Fate Therapeutics Inc Earnings Call TranscriptNov 05, 2020$49.92 (+0.20%)Earnings
- Q2 2020 Fate Therapeutics Inc Earnings Call TranscriptAug 05, 2020$32.84 (+0.67%)Earnings
- Q1 2020 Fate Therapeutics Inc Earnings Call TranscriptMay 11, 2020$30.22 (+4.79%)Earnings
- Q4 2019 Fate Therapeutics Inc Earnings Call TranscriptMar 02, 2020$31.01 (+6.20%)Earnings
- Q3 2019 Fate Therapeutics Inc Earnings Call TranscriptNov 05, 2019$15.71 (+2.68%)Earnings
- Fate Therapeutics, Inc. Presents at Citi's 14th Annual Biotech Conference, Sep-04-2019 01:30 PM TranscriptSep 04, 2019
- Q2 2019 Fate Therapeutics Inc Earnings Call TranscriptAug 06, 2019$19.82 (+2.85%)Earnings
- Q1 2019 Fate Therapeutics Inc Earnings Call TranscriptMay 07, 2019$16.98 (-5.19%)Earnings
- Q4 2018 Fate Therapeutics Inc Earnings Call TranscriptMar 05, 2019$16.03 (-1.05%)Earnings
Fate Therapeutics Inc Interim Phase 1 Clinical Data for NHL Programs Call Transcript
Good afternoon. This is Scott Wolchko, President and CEO of Fate Therapeutics, and thank you all for joining us. We are excited to share with you today interim Phase I clinical data for FT516 and FT506 off-the-shelf, iPS-derived NK cell programs in relapsed refractory B-cell lymphoma.
Please note, as we discuss our FT516 and 596 programs today, our comments will include forward-looking statements that involve risks and uncertainties. These risks and uncertainties are detailed in our SEC filings, and I refer you to our most recent Form 10-Q filed with the SEC for full disclosure of these factors. Note that undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made as the facts and circumstances underlying these forward-looking statements may change.
Joining me on today's call are Dr. Wayne Chu, our Senior Vice President of Clinical Development; Dr. Sarah Cooley, our Senior Vice President of Clinical Translation; and Dr. Bob Valamehr, our Chief Research
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)